Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM3FXMA)

• Drug Name: Naloxone Drug Info
• Synonyms: Nalone; Nalossone; Naloxona; Naloxonum; Narcan; Narcanti; Narcon; DBL Naloxone; Nalossone [DCIT]; Naloxone HCl; EN 1530base; DBL Naloxone (TN); L-Naloxone; N-Allylnoroxymorphone; Nalone (TN); Naloxona [INN-Spanish]; Naloxone (INN); Naloxone [INN:BAN]; Naloxonum [INN-Latin]; Narcan (TN); Narcanti (TN); N-Allyl-noroxymorphone; L-N-Allyl-14-hydroxynordihydromorphinone; L-N-Allyl-7,8-dihydro-14-hydroxynormorphinone; N-Allyl-4,5alpha-epoxy-3,14-dihydroxy-6-morphinanon; Morphinan-6-one, 17-allyl-4,5alpha-epoxy-3,14-dihydroxy-(8CI); Morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-17-(2-propenyl)-, (5alpha)-(9CI); (-)-N-allyl-14-hydroxynordihydroxymorphinan-6-one; (-)-Naloxone; (5alpha)-3,14-dihydroxy-17-prop-2-en-1-yl-4,5-epoxymorphinan-6-one; (5alpha)-4,5-Epoxy-3,14-dihydroxy-17-(2-propenyl)morphinan-6-one; 1-N-Allyl-14-hydroxynordihydromorphinone; 1-N-Allyl-7,8-dihydro-14-hydroxynormorphinone; 12-Allyl-7,7a,8,9-tetrahydro-3,7a-dihydroxy-4aH-8,9c-iminoethanophenanthro(4,5-bcd)furanone; 12-Allyl-7,7a,8,9-tetrahydro-3,7a-dihydroxy-4aH-8,9c-iminoethanophenanthro[4,5-bcd]furan-5(6H)-one; 17-Allyl-4,5-alpha-epoxy-3,14-dihydroxymorphinan-6-one; 17-Allyl-4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one; 17-allyl-3,14-dihydroxy-4,5alpha-epoxymorphinan-6-one; 3,14-dihydroxy-17-(prop-2-en-1-yl)-4,5alpha-epoxymorphinan-6-one
• Therapeutic Class: Antinarcotic Agents
• Cross-matching ID:
  PubChem CID: 5284596
  ChEBI ID: CHEMBL80
  CAS Number: CAS 465-65-6
  TTD Drug ID: D0X3FX
  VARIDT Drug ID: DR00698

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Propanoate metabolism	2.14	0.00e+0	30/34 (88.24%)	DLD;ALDH6A1;LDHB;...
beta-Alanine metabolism	2.05	0.00e+0	25/30 (83.33%)	DPYD;DPYS;ALDH6A1;...
DNA replication	1.98	2.87e-3	34/36 (94.44%)	MCM5;FEN1;POLE2;...
Pyruvate metabolism	1.89	6.45e-3	41/47 (87.23%)	DLD;ADH1B;GLO1;...
Fatty acid degradation	1.88	5.16e-3	40/43 (93.02%)	ADH1B;ECI2;ALDH3A2;...
Valine, leucine and isoleucine degradation	1.88	4.30e-3	42/48 (87.5%)	DLD;HMGCS2;ALDH6A1;...
Dilated cardiomyopathy	1.80	1.23e-2	86/96 (89.58%)	DMD;TNNC1;TTN;...
Glycolysis / Gluconeogenesis	1.77	1.51e-2	56/67 (83.58%)	DLD;ADH1B;ALDOB;...
Cell cycle	1.74	2.58e-2	110/124 (88.71%)	MCM5;CDK1;PLK1;...
Oocyte meiosis	1.74	2.32e-2	90/129 (69.77%)	CDK1;PLK1;SKP1;...
D-Glutamine and D-glutamate metabolism	1.73	2.11e-2	5/5 (100%)	GLS2;GLS;GLUD1;...
Drug metabolism	1.73	2.01e-2	78/151 (51.66%)	GSTA1;ADH1B;DPYD;...
Base excision repair	1.72	2.05e-2	29/33 (87.88%)	FEN1;POLE2;PCNA;...
Linoleic acid metabolism	1.71	2.46e-2	21/29 (72.41%)	CYP2C8;CYP2J2;ALOX15;...
Mismatch repair	1.70	2.41e-2	22/23 (95.65%)	PCNA;MSH6;RFC3;...
Citrate cycle (TCA cycle)	1.64	4.73e-2	30/30 (100%)	DLD;IDH3A;MDH1;...
Primary bile acid biosynthesis	1.64	4.55e-2	15/17 (88.24%)	CH25H;HSD17B4;AKR1D1;...
Fluid shear stress and atherosclerosis	-1.69	4.79e-2	123/139 (88.49%)	IL1A;PDGFA;IKBKB;...
Yersinia infection	-1.70	5.00e-2	120/137 (87.59%)	PIK3R3;MAPK10;CRK;...
Lysosome	-1.74	3.34e-2	115/128 (89.84%)	ATP6V0B;CLTA;ATP6V0D1;...
Rheumatoid arthritis	-1.77	2.56e-2	78/93 (83.87%)	CTSK;ITGB2;TLR2;...
Transcriptional misregulation in cancer	-1.77	2.88e-2	158/192 (82.29%)	PAX8;PDGFA;LYL1;...
NOD-like receptor signaling pathway	-1.81	2.14e-2	145/181 (80.11%)	RNASEL;GABARAPL1;NAMPT;...
NF-kappa B signaling pathway	-1.86	1.15e-2	90/104 (86.54%)	IKBKB;TICAM1;PLAU;...
Steroid biosynthesis	-1.92	6.92e-3	19/20 (95%)	DHCR24;LSS;FDFT1;...
TNF signaling pathway	-1.99	5.77e-3	103/112 (91.96%)	PIK3R3;MAPK10;CSF2;...
Mineral absorption	-2.00	7.69e-3	48/60 (80%)	HEPH;TRPV6;SLC26A6;...
Pertussis	-2.08	5.77e-3	64/76 (84.21%)	MAPK10;CXCL6;NOS2;...
IL-17 signaling pathway	-2.32	0.00e+0	84/94 (89.36%)	RELA;JUN;TRAF3IP2;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone

Osteosarcoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
U-2 OS	CVCL_0042	Homo sapiens	6.66uM - 10uM	6H	Hide ▲

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	10uM	6H, 24H	Hide ▲

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	10uM	6H, 24H	Show ▼

Hematopoietic system

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
ASC	CVCL_U602	Homo sapiens	10uM	24H	Show ▼

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	10uM	6H, 24H	Show ▼

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	10uM	6H	Show ▼

Hepatocellular carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HuH-7	CVCL_0336	Homo sapiens	10uM	72H	Show ▼

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	10uM	6H, 24H	Show ▼

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	10uM	6H, 24H	Show ▼

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	1.11uM - 10uM	6H, 24H	Show ▼
VCaP	CVCL_2235	Homo sapiens	10uM	6H, 24H	Show ▼

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	1.11uM - 10uM	6H, 24H	Show ▼